ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
30.77
0.59
(1.95%)
Closed July 26 4:00PM
30.68
-0.095
(-0.31%)
After Hours: 7:59PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
30.68
Bid
-
Ask
-
Volume
35,619,165
30.01 Day's Range 30.88
25.20 52 Week Range 37.345
Market Cap
Previous Close
30.18
Open
30.08
Last Trade
15
@
30.69
Last Trade Time
Financial Volume
$ 1,091,577,771
VWAP
30.6458
Average Volume (3m)
35,024,741
Shares Outstanding
5,666,592,898
Dividend Yield
5.44%
PE Ratio
82.29
Earnings Per Share (EPS)
0.37
Revenue
58.5B
Net Profit
2.12B

About Pfizer Inc

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New York, New York, USA
Founded
1970
Pfizer Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PFE. The last closing price for Pfizer was $30.18. Over the last year, Pfizer shares have traded in a share price range of $ 25.20 to $ 37.345.

Pfizer currently has 5,666,592,898 shares outstanding. The market capitalization of Pfizer is $171.02 billion. Pfizer has a price to earnings ratio (PE ratio) of 82.29.

Pfizer (PFE) Options Flow Summary

Overall Flow

Bullish

Net Premium

241M

Calls / Puts

2,327.59%

Buys / Sells

118.15%

OTM / ITM

9.83%

Sweeps Ratio

0.03%

PFE Latest News

European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9) after up to four years of...

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.792.6430244228829.8930.9329.313476624729.85507627CS
42.739.7674418604727.9530.9327.2953179198729.08875421CS
122.8210.122038765327.8630.9326.873502474128.52995695CS
263.0611.078928312827.6230.9325.23969336727.60223551CS
52-6.19-16.788717114236.8737.34525.23697211629.15160952CS
156-10.94-26.285439692541.6261.7125.23050914240.09945875CS
260-11.98-28.082512892642.6661.7125.22992724238.81824351CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.56M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.54M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
258.54k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.9M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
715.97k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.01M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
406.8M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.54M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.25M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.45M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.66M

PFE Discussion

View Posts
Nebuchadnezzar Nebuchadnezzar 4 hours ago
PFE back in the $30s :)
👍️0
Vexari Vexari 2 days ago
What created Hemophilia-A

Why does it exist
👎️ 1 💩 1 🗑️ 1 🤡 1 🦤 1
DewDiligence DewDiligence 2 days ago
PFE GT for Hemophilia-A meets phase-3 endpoints:

https://finance.yahoo.com/news/pfizer-announces-positive-topline-results-104500301.html The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment. Following a single 3e13 vg/kg dose, giroctocogene fitelparvovec demonstrated a statistically significant reduction in mean total ABR compared to the pre-infusion period (1.24 vs 4.73; one-sided p-value=0.0040).

Key secondary endpoints as defined by the trial protocol were met and also demonstrated superiority compared to prophylaxis. 84% of participants maintained FVIII activity >5% at 15 months post-infusion (one-sided p-value = 0.0086) with the majority of participants having FVIII activity ≥15%, and the mean treated ABR showed a statistically significant 98.3% reduction from 4.08 in the pre-infusion period to 0.07 post-infusion (from Week 12 up to at least 15 months [15-44 months]; one-sided p-value < 0.0001). Throughout the study, among all dosed participants, one participant (1.3%) returned to prophylaxis post-infusion. BMRN has an FDA-approved GT for hemophilia-A called Roctavian (#msg-172243819), but the sales to date have been de minimis (#msg-173910310).

Note: PFE’s giroctocogene fitelparvovec for hemophilia-A should not be confused with Beqvez, PFE’s FDA-approved GT for hemophilia-B (#msg-174309616).
👍️0
FALCON1 FALCON1 2 days ago
Zacks' Research Report on Pfizer,...
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
👍️0
axelvento axelvento 2 days ago
"from where I'm looking, the world is flat." NO VAX LOL
👍️ 1 😄 1
axelvento axelvento 2 days ago
Sangamo Therapeutics (NASDAQ: SGMO) and Pfizer (NYSE: PFE) have reported positive Phase 3 results for giroctocogene fitelparvovec, a gene therapy for hemophilia A. The AFFINE trial met its primary and key secondary objectives, demonstrating superiority over routine Factor VIII replacement therapy in reducing annualized bleeding rates. A single dose of the therapy significantly reduced mean total ABR from 4.73 to 1.24, with 84% of participants maintaining Factor VIII activity >5% at 15 months post-infusion. The therapy was generally well-tolerated. Sangamo is eligible for substantial milestone payments and royalties if the therapy is approved and commercialized. Pfizer plans to discuss the data with regulatory authorities soon.
👍️0
Vexari Vexari 3 days ago
Must have been a weaker version

Testing

Isn't what it used to be
Tenth day of Paxlovid (not tenth course) Keep on keeping on

Until the dose

Is done
💤 1 💩 1 🤡 1 🤢 1 🤮 1
DewDiligence DewDiligence 3 days ago
Tenth day of Paxlovid (not tenth course).
👍️0
axelvento axelvento 3 days ago
President Biden finished his 10th course of Paxlovid today; symptoms have resolved “almost completely,” update from his physician says:

https://www.whitehouse.gov/wp-content/uploads/2024/07/Letter7.22.2024.pdf
👌 1 👍️ 1
PowerPlay1 PowerPlay1 4 days ago
Once we get closer to NOV 2024 PFE going to start inching up will see high 35sss plus

Trump 2024 !!!
👍️0
axelvento axelvento 4 days ago
https://www.whitehouse.gov/wp-content/uploads/2024/07/Letter-7.21.24.pdf
👍️ 1 😀 1
Vexari Vexari 6 days ago
How does one know this

What test was used

Why Paxlovid
💩 1 🤡 1 🤪 1 🦃 1 🦤 1
axelvento axelvento 7 days ago
President Biden tests positive for Covid with mild symptoms, per White House, and has received first dose of Paxlovid
👍️0
Vexari Vexari 1 week ago
It's a mind thing

Without having to think
💩 2 🤡 1 🤪 1 🦤 1 🪞 1
Monroe1 Monroe1 1 week ago
Giving Planned Obsolescence a new replacement.
👍️0
Vexari Vexari 1 week ago
The basic premise of wellness

Is being turned on its head

Perception of wellness

While making one sick

No need to worry

Have something for that

Another form of

Predictive programming
👍️0
Monroe1 Monroe1 1 week ago
https://mypatriotsnetwork.com/big-pharma-protections-under-attack-as-americans-fight-back/?utm_name=Id
👍️0
Monroe1 Monroe1 1 week ago
I was hoping it would dip to 22 and would have bot a few to flip. I think it will probably climb but there are head winds and lots of analysts are doubting the latest strategies.
👍️0
Monroe1 Monroe1 1 week ago
for certain. will be waiting.
👍️0
Vexari Vexari 1 week ago
What happens when the scam is revealed

Totally against the grain

But true
👎️ 1 💩 1 🤡 1 🤪 1 🦤 1
axelvento axelvento 1 week ago
I agree 1000%

Stock Dividend $$$$$$$$$
👍️0
Nebuchadnezzar Nebuchadnezzar 1 week ago
good news from their latest acquisition, or the accretive benefits of it or a dividend hike or stock buyback announcement

also a safe haven money rotation play as rates come down a little

PFE has been one of the worst trading stocks in months, i think it truly bottomed out

$25-27 was a great buy area imo
👍️0
Vexari Vexari 1 week ago
What is the control mechanism

That makes it so
👎️ 1 💩 1 🤡 1 🤪 1 🪳 1
Nebuchadnezzar Nebuchadnezzar 1 week ago
if UNH can surge $33 in one day, PFE can surge $2-$4 in one day
👍️0
Monroe1 Monroe1 1 week ago
It has been a year since that happened. I predicted this climb which is why I covered my shorts. 35 would be a good place to short again but most likely there will be set backs before reaching it. Bares watching,,, or should I say bears watching. Too bad this isn't an honest company.
👍️0
Vexari Vexari 1 week ago
Still trying to figure out

What is wrong with

The human immune system

Where it would need

So much help

Poisoning aside
💩 1 🗑️ 1 🤡 1 🤪 1 🦤 1
Nebuchadnezzar Nebuchadnezzar 1 week ago
PFE going back to $35
👍️0
Vexari Vexari 2 weeks ago
Us and Them

Pink Floyd
💩 1 🤡 1 🤮 1 🦤 1
axelvento axelvento 2 weeks ago
THE WRITING IS ON THE WALL
👍️0
Vexari Vexari 2 weeks ago
Rather than cite

It would be nice

To give an explanation

Have any of one's own words

To go behind what one posts

Curious
👎️ 1 💩 1 🤡 1 🦤 1 🪳 1
Monroe1 Monroe1 2 weeks ago
If you are long....why? Ok, I get it. But to continue is rubber stamping the company that killed your family and fellow citizens of the world.
Even Redfield finally admits it. "Redfield went further, admitting that the spike protein produced by mRNA vaccines is “toxic to the body” and triggers “a very strong pro-inflammatory response.”

https://childrenshealthdefense.org/defender/robert-redfield-mrna-covid-vaccine-risk/?utm_id=20240712
👎️ 1 💩 1 🗑️ 1 🦤 1
Monroe1 Monroe1 2 weeks ago
Well maybe https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering?oly_enc_id=4924G0643390I0A
👍️0
Trend-Setter Trend-Setter 2 weeks ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
👍️0
axelvento axelvento 2 weeks ago
https://www.biospace.com/article/pfizer-moves-forward-with-obesity-pill-plans-dose-optimization-studies-this-year/
👍️ 1 😀 1
Vexari Vexari 2 weeks ago
May the space
Be with you
💤 1 💩 1 🤡 1 🤪 1 🦤 1
axelvento axelvento 2 weeks ago
“Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several preclinical candidates," said Pfizer's chief scientific officer, Mikael Dolsten.

"The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space."
👍️ 2 😀 1
Monroe1 Monroe1 2 weeks ago
The patent lawsuit in Germany will chop Pfizer down to size if this doesn't work out in their favor. This bears paying close attention.
😎 1
Vexari Vexari 2 weeks ago
For what ails humanity

Proverbial

Hamster wheel

Until a cure

With what they've got

Keep on running

While adding on

Never ending cycle

None of it is good
👍️ 1 👎️ 1 💩 1 🤡 1 🤪 1 🦤 1
Monroe1 Monroe1 2 weeks ago
TÜBINGEN, Germany/BOSTON, USA – July 11, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.



The U.S. trial against Pfizer/BioNTech will take place on March 3, 2025, before the U.S. District Court of the Eastern District of Virginia. A previously issued court recommendation to stay the proceedings for all 10 U.S. patents was withdrawn. The recommendation had followed a motion by Acuitas Therapeutics to intervene, sever and stay proceedings based on co-owner and co-inventorship claims. It was resolved after both companies reached a settlement in April 2024, which provided Acuitas licenses to several patents, including three out of four disputed U.S. patents. These three patents have been withdrawn from the U.S. patent litigation against Pfizer/BioNTech. In return, Acuitas acknowledges that CureVac is the sole owner of the disputed patents.



Litigation in Europe will continue March 25, 2025, with a hearing on the validity of EP 3 708 668 B1 (split poly-A tail technology), before the Opposition Division of the European Patent Office. The infringement action in relation to this patent was previously suspended pending the validity determination by the European Patent Office. In the German patent litigation against Pfizer/BioNTech, the settlement with Acuitas Therapeutics led to the withdrawal of two utility models covering equivalent claims to the three patents withdrawn in the United States. As previously announced, a hearing before the infringement court of Düsseldorf covering the European patent EP 4 023 755 B1 (split poly-A tail technology) and the utility model DE 20 2021 004 130 U1 (COVID-19 vaccine design), is scheduled for September 10, 2024.



Furthermore, a trial in the UK has started on July 10, 2024. It is based on a declaration of non-infringement and request for revocation by Pfizer/BioNTech in the UK for the two CureVac patents EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A-tail technology). CureVac counterclaimed for infringement. A judgement is expected later in 2024. The trial for the further involved patent EP 1 857 122 B1 (G/C enrichment technology) will be set for a later time point.
👍️ 1
Monroe1 Monroe1 2 weeks ago
I hope the oral version has better efficacy than the Covid Paxlovid.
👍️0
Monroe1 Monroe1 2 weeks ago
Wonder if he was one of the lucky ones working at Pfizer who did not choose the jab? Could be he took that special jab not offered to the public similar to the ones offered to Pfizer employees over in Australia. Who knows what is he feeling or thinking. Could be he is suffering and wants to play hard with his blood money before his next infarction. Hard to say. For his sake I hope his conscious is clean and his health is good. Amen.
👍️0
ziploc_1 ziploc_1 2 weeks ago
I anticipate that there will be a market for those patients, who have reached a point, where they are ready to discontinue injections of weight loss meds...but still want to continue with an oral weight loss med.
👍️0
DewDiligence DewDiligence 2 weeks ago
There’s discussion of the Danuglipron news on the Biotech Values board today.
👍️0
ziploc_1 ziploc_1 2 weeks ago
Dolsten,at age 66 ,with estimated net worth at over $50 million, is unlikely to be looking for challenging new employment..
👍️0
DewDiligence DewDiligence 2 weeks ago
But the PR did not say Dolsten was retiring, which it surely would have done if that were the case.
👍️ 1
ziploc_1 ziploc_1 2 weeks ago
"https://seekingalpha.com/news/4123562-pfizer-advances-development-of-once-daily-weight-loss-pill"

Pfizer's ORAL weight loss med IMO, would take significant market share away from the products, which are now on the market...since the competing meds need be taken by weekly INJECTIONS (even if the Pfizer med proves to be slightly less effective)...This would be especially true for patients, who disdain the nuisance and discomfort of injecting themselves on a weekly basis.
👍️0
ziploc_1 ziploc_1 2 weeks ago
'OUSTING' is probably the wrong word...Dolsten is 66 years old...and he probably thought it was time to retire and enjoy his fortune, achieved through being awarded millions of Pfizer shares over his 15 years with the company.
👍️ 1
Vexari Vexari 2 weeks ago
That is the question

A unique breed

Nonetheless
👍️ 1 💩 1 🤡 1 🤮 1 🦃 1 🦤 1
DewDiligence DewDiligence 2 weeks ago
PFE ousts CSO:

https://www.businesswire.com/news/home/20240709792921/en
👍️0
Monroe1 Monroe1 2 weeks ago
Who would consent knowing this?
https://petermcculloughmd.substack.com/p/a-pandoras-box-in-the-pharma-lab?publication_id=1119676&post_id=146401978&triggerShare=true&isFreemail=true&r=x7hm&triedRedirect=true
Well, PFE just shoots from the hip. No toxicology studies? OMG
Oh heck, they mean well. Guess I'll just bend over.

Knowing some of the facts that have been exposed....who in their right mind would invest in this company except to squeeze some profit from the pps movement?
👍️0